---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-026280"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-08-06T20:17:59+00:00"
generated_at: "2026-08-06T20:21:22.206655+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaxart reports Q2 2026 net loss $13.5M; Phase 2b sentinel safety data positive

## Summary
- Net loss $13.5M ($0.06 per share) vs $15.0M loss in Q2 2025; revenue $27.2M (down from $39.7M).
- Cash $64.0M; runway into Q2 2027; BARDA contract total authorized funding $344.8M.
- Phase 2b sentinel cohort (400 participants) showed no vaccine-related SAEs; most common AEs: fatigue, headache.
- Topline efficacy data from full ~5,000-participant study expected H1 2027.
- R&D expenses $33.7M (down 32% YoY); G&A $6.6M (up 43% YoY).

## SEC filing metadata
- accession: 0001437749-26-026280
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-08-06T20:17:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/0001437749-26-026280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/vxrt20260806_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-026280
- JSON: https://secwatch.observer/filing/0001437749-26-026280.json
- Plain text: https://secwatch.observer/filing/0001437749-26-026280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.